Table 1.
Demographic and clinical characteristics of patient groups.
| Demographic and clinical characteristics | GRE (n = 15) | Non-GRE (n = 15) | Healthy (n = 20) | p-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 8 | 7 | 9 | 0.88 |
| Female | 7 | 8 | 11 | |
| Age (y)* | 38.2 ± 3.4 | 41.4 ± 3.1 | 38.0 ± 1.9 | 0.63 |
| Handness | ||||
| Right | 15 | 15 | 20 | − |
| Left | 0 | 0 | 0 | |
| KPS score (preoperative) | ||||
| 100 | 15 | 14 | 20 | |
| 90~100 | 0 | 1 | 0 | > 0.99 |
| 80~90 | 0 | 0 | 0 | |
| Education level (y)* | 12.8 ± 1.2 | 13.2 ± 1.1 | 12.7 ± 0.8 | 0.13 |
| Histopathology | ||||
| Astrocytoma | 7 | 8 | – | 0.71 |
| Oligodendroglioma | 8 | 7 | – | |
| IDH status | ||||
| Mutation | 9 | 10 | ||
| Wild-type | 6 | 5 | 0.71 | |
| Tumor volume (mL)* | 44.83 ± 8.37 | 38.57 ± 10.16 | – | 0.64 |
| Onset age (y)* | 38.15 ± 1.9 | – | ||
| Frequency before diagnosis | ||||
| Low (only once) | 12 | |||
| Medium (2~3 times) | 2 | – | ||
| High (>3 times) | 1 | |||
| Preoperative anti-epileptic drugs | – | |||
| Levetiracetam (0.5 g, twice a day) | 15 | |||
| Postoperative epileptic control | – | |||
| Engel Class I | 15 | |||
*
Values are means ± standard deviations, unless indicated otherwise.
Using Mann-Whitney U test to compare differences in the Karnofsky performance status between the GRE and non- GRE groups.
Using Student's t-test to compare differences in tumor volume between the GRE and non-GRE groups.
Using one-way ANOVA test to compare differences in age and education level between the GRE and non-GRE groups.
Using chi-squared test to compare differences in sex, tumor location, and IDH status between the GRE and non-GRE groups.
IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status.